{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:27Z","timestamp":1787063067642,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Janus kinase inhibitors are antirheumatic immunosuppressive drugs that target intracellular Janus kinases (JAKs). Baricitinib is a selective and reversible orally administered JAK1\/JAK2 inhibitor approved for treating rheumatoid arthritis, atopic dermatitis, and alopecia areata in adult patients. Expanded access to baricitinib has been approved for treating pediatric patients affected by rare Mendelian autoinflammatory diseases with type I interferon-mediated damage. Knowledge of the pharmacokinetic properties and target plasma levels of baricitinib in pediatric patients is limited. In this study, a novel LC-MS\/MS method for measuring baricitinib in plasma, validated according to the ICH M10 guidelines, is presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Sample preparation was performed by adding 10 \u00b5L of IS working solution (150 ng\/mL) and 200 \u00b5L of MeOH to each plasma sample. Chromatographic separation was conducted using a Thermo Scientific Accucore Polar Premium column (50 mm \u00d7 2.1 mm, i.d. 2.6 m). This method was applied to 7 real anonymous plasma samples obtained from pediatric patients treated with baricitinib at IRCCS Istituto Giannina Gaslini (Genoa, Italy). Patients of both sexes had a median age of 14 years (range, 10\u201317 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The LC-MS\/MS method resulted linear over wide concentration ranges (1.024\u2013100 ng\/mL) and was accurate and reproducible in the absence of matrix effects, allowing for robust, specific, and rapid quantification of baricitinib from a low amount of plasma (50 \u00b5L). The plasma concentration of baricitinib in the samples of the patients, expressed as mean \u00b1 SD, was 11.25 \u00b1 10.86 ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This novel LC-MS\/MS method is suitable for the therapeutic drug monitoring of baricitinib and can help guide therapy optimization in pediatric patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001128","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:40:10Z","timestamp":1695775210000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A Novel LC-MS\/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients"],"prefix":"10.1097","volume":"46","author":[{"given":"Alessia","family":"Cafaro","sequence":"first","affiliation":[{"name":"Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giammarco","family":"Baiardi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pharmacology, and Toxicology Unit, University of Genoa, Viale Benedetto XV;"},{"name":"Clinical Pharmacology Unit, EO Ospedali Galliera, Mura delle Cappuccine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pigliasco","sequence":"additional","affiliation":[{"name":"Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Barco","sequence":"additional","affiliation":[{"name":"Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pharmacology, and Toxicology Unit, University of Genoa, Viale Benedetto XV;"},{"name":"Clinical Pharmacology Unit, EO Ospedali Galliera, Mura delle Cappuccine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Volpi","sequence":"additional","affiliation":[{"name":"UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[{"name":"UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[{"name":"UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cangemi","sequence":"additional","affiliation":[{"name":"Chromatography and Mass Spectrometry Section, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/fcp.12586","article-title":"Potential drug\u2013drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments","volume":"34","author":"Lemaitre","year":"2020","journal-title":"Fundam Clin Pharmacol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/psp4.12251","article-title":"Dose\/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis","volume":"6","author":"Zhang","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, safety, and tolerability of single- and multiple-dose once-daily baricitinib in healthy Chinese subjects: a randomized placebo-controlled study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"key":"R9-20250603","first-page":"60","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"23","author":"Genovese","year":"2016","journal-title":"N Engl J Med."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Montealegre Sanchez","year":"2018","journal-title":"J Clin Invest."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinic","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High throughput routine determination of 17 tyrosine kinase inhibitors by LC\u2013MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol Lett."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200202000-00001","article-title":"Review: therapeutic drug monitoring in pediatrics","volume":"24","author":"Soldin","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"113273","DOI":"10.1016\/j.jpba.2020.113273","article-title":"A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients","volume":"186","author":"Barco","year":"2020","journal-title":"J Pharm Biomed Anal."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FTD.0000000000000600","article-title":"LC-MS\/MS-Based quantification of 9 antiepileptic drugs from a dried sample spot device","volume":"41","author":"D'urso","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/biomedicines9101379","article-title":"A UHPLC\u2013MS\/MS method for therapeutic drug monitoring of aciclovir and ganciclovir in plasma and dried plasma spots","volume":"9","author":"Pigliasco","year":"2021","journal-title":"Biomedicines"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines11020530","article-title":"Development and validation of a novel LC-MS\/MS method for a TDM-guided personalization of HSCT conditioning with high-dose busulfan in children","volume":"11","author":"Cafaro","year":"2023","journal-title":"Biomedicines"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/molecules25071600","article-title":"A hydrophilic interaction liquid chromatography\u2013tandem mass spectrometry quantitative method for determination of baricitinib in plasma, and its application in a pharmacokinetic study in rats","volume":"25","author":"Ezzeldin","year":"2020","journal-title":"Molecules"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3797\/scipharm.1510-08","article-title":"Simultaneous quantification of baricitinib and methotrexate in rat plasma by LC-MS\/MS: application to a pharmacokinetic study","volume":"84","author":"Veeraraghavan","year":"2016","journal-title":"Sci Pharm."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T13:07:40Z","timestamp":1748956060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001128","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"2023-02-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}